Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 49

1.

Treating cancer with genetically engineered T cells.

Park TS, Rosenberg SA, Morgan RA.

Trends Biotechnol. 2011 Nov;29(11):550-7. doi: 10.1016/j.tibtech.2011.04.009. Epub 2011 Jun 12. Review.

2.

Real-time analysis of T cell receptors in naive cells in vitro and in vivo reveals flexibility in synapse and signaling dynamics.

Friedman RS, Beemiller P, Sorensen CM, Jacobelli J, Krummel MF.

J Exp Med. 2010 Nov 22;207(12):2733-49. doi: 10.1084/jem.20091201. Epub 2010 Nov 1.

3.

Improved survival with ipilimumab in patients with metastatic melanoma.

Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ.

N Engl J Med. 2010 Aug 19;363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 Jun 5. Erratum in: N Engl J Med. 2010 Sep 23;363(13):1290.

4.

Macrophage diversity enhances tumor progression and metastasis.

Qian BZ, Pollard JW.

Cell. 2010 Apr 2;141(1):39-51. doi: 10.1016/j.cell.2010.03.014. Review.

5.

Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade.

Lu H, Wagner WM, Gad E, Yang Y, Duan H, Amon LM, Van Denend N, Larson ER, Chang A, Tufvesson H, Disis ML.

J Immunol. 2010 May 1;184(9):5360-7. doi: 10.4049/jimmunol.0902997. Epub 2010 Mar 22.

6.

CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages.

DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, Kolhatkar N, Coussens LM.

Cancer Cell. 2009 Aug 4;16(2):91-102. doi: 10.1016/j.ccr.2009.06.018.

7.

Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism.

Norian LA, Rodriguez PC, O'Mara LA, Zabaleta J, Ochoa AC, Cella M, Allen PM.

Cancer Res. 2009 Apr 1;69(7):3086-94. doi: 10.1158/0008-5472.CAN-08-2826. Epub 2009 Mar 17.

8.

Trophic macrophages in development and disease.

Pollard JW.

Nat Rev Immunol. 2009 Apr;9(4):259-70. doi: 10.1038/nri2528. Review.

9.

High-density gene expression analysis of tumor-associated macrophages from mouse mammary tumors.

Ojalvo LS, King W, Cox D, Pollard JW.

Am J Pathol. 2009 Mar;174(3):1048-64. doi: 10.2353/ajpath.2009.080676. Epub 2009 Feb 13.

10.

Myeloid-derived suppressor cells as regulators of the immune system.

Gabrilovich DI, Nagaraj S.

Nat Rev Immunol. 2009 Mar;9(3):162-74. doi: 10.1038/nri2506. Review.

11.

Visualizing stromal cell dynamics in different tumor microenvironments by spinning disk confocal microscopy.

Egeblad M, Ewald AJ, Askautrud HA, Truitt ML, Welm BE, Bainbridge E, Peeters G, Krummel MF, Werb Z.

Dis Model Mech. 2008 Sep-Oct;1(2-3):155-67; discussion 165. doi: 10.1242/dmm.000596. Epub 2008 Sep 18.

12.

Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells.

Epardaud M, Elpek KG, Rubinstein MP, Yonekura AR, Bellemare-Pelletier A, Bronson R, Hamerman JA, Goldrath AW, Turley SJ.

Cancer Res. 2008 Apr 15;68(8):2972-83. doi: 10.1158/0008-5472.CAN-08-0045.

13.

Dendritic cell-induced memory T cell activation in nonlymphoid tissues.

Wakim LM, Waithman J, van Rooijen N, Heath WR, Carbone FR.

Science. 2008 Jan 11;319(5860):198-202. doi: 10.1126/science.1151869.

14.

Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer.

Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, Herber DL, Schneck J, Gabrilovich DI.

Nat Med. 2007 Jul;13(7):828-35. Epub 2007 Jul 1.

15.

Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer.

Anderson MJ, Shafer-Weaver K, Greenberg NM, Hurwitz AA.

J Immunol. 2007 Feb 1;178(3):1268-76. Erratum in: J Immunol. 2007 Nov 15;179(10):7184.

16.

Random migration precedes stable target cell interactions of tumor-infiltrating T cells.

Mrass P, Takano H, Ng LG, Daxini S, Lasaro MO, Iparraguirre A, Cavanagh LL, von Andrian UH, Ertl HC, Haydon PG, Weninger W.

J Exp Med. 2006 Nov 27;203(12):2749-61. Epub 2006 Nov 20.

17.

Macrophages regulate the angiogenic switch in a mouse model of breast cancer.

Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, Qian H, Xue XN, Pollard JW.

Cancer Res. 2006 Dec 1;66(23):11238-46. Epub 2006 Nov 17.

18.

Mechanisms of immune evasion by tumors.

Drake CG, Jaffee E, Pardoll DM.

Adv Immunol. 2006;90:51-81. Review.

PMID:
16730261
19.

Adoptive immunotherapy for cancer: building on success.

Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo NP.

Nat Rev Immunol. 2006 May;6(5):383-93. Review.

20.

Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma.

Rosenberg SA, Sherry RM, Morton KE, Scharfman WJ, Yang JC, Topalian SL, Royal RE, Kammula U, Restifo NP, Hughes MS, Schwartzentruber D, Berman DM, Schwarz SL, Ngo LT, Mavroukakis SA, White DE, Steinberg SM.

J Immunol. 2005 Nov 1;175(9):6169-76.

Supplemental Content

Support Center